1/ 🔬🧫Tumoral lactic acid bacteria can rewire tumor metabolism and drive cancer treatment response. Our @cancercell paper is finally out #openaccess online! 🦠🔬
tinyurl.com/56puk8bx
Do you want to use patient-derived organoids to model cervical cancer? Our group (study led by staff scientist Rui Wang!) did the hard troubleshooting for you and published it as an easy-to-follow protocol 🤗
star-protocols.cell.com/prot…
Dr. Benjamin Schrank explains his recent research on a first-in-class antibody-drug conjugate that is designed to trigger an immune response, as a complementary strategy to radiation therapy.
Read more: bit.ly/3XXRmWW@BenjaminSchrank#ASTRO24#EndCancer
@BenjaminSchrank is without a doubt one of the very best physician scientist trainee I have ever encountered. Quadruple threat: great scientist, leadership skills, gifted educator and super kind/humble. Truly exceptional. He’s also on the job market. So proud!
Dr. Benjamin Schrank explains his recent research on a first-in-class antibody-drug conjugate that is designed to trigger an immune response, as a complementary strategy to radiation therapy.
Read more: bit.ly/3XXRmWW@BenjaminSchrank#ASTRO24#EndCancer
Fantastic work by one of our PGY5 aspiring physician scientists! @Vince_BernPag is the real deal and a total phys sci superstar - it’s amazing to see this project develop from the beginning to these great discoveries and looking forward to how his work will impact patients
What's new in enhancing gynecologic outcomes?
Meet our experts, Drs. Lauren Colbert and Ann Klopp, in booth 741 to learn more at 11 a.m. EDT. @colbertle@AnnKloppMD (3/4) #ASTRO24#EndCancer
ALT Meet the Experts - Enhancing Gynecologic Outcomes: New Standards. Booth 741
What's new in enhancing gynecologic outcomes?
Meet our experts, Drs. Lauren Colbert and Ann Klopp, in booth 741 to learn more at 11 a.m. EDT. @colbertle@AnnKloppMD (3/4) #ASTRO24#EndCancer
ALT Meet the Experts - Enhancing Gynecologic Outcomes: New Standards. Booth 741
A first-in-class antibody-drug conjugate works by targeting protein CD47, which helps immune cells activate and engulf cancer cells. The drug triggers an adaptive immune response to help eliminate the tumor. Learn more about the research, which Dr. Ben Schrank will present at #ASTRO24: bit.ly/3XXRmWW#EndCancer
1 in 3 men to receive RP or EBRT for treatment of localized #ProstateCancer reported “moderate to big problems” with sexual function 10 years later, according to a new longterm study at #ASTRO24.
Read more longterm functional outcomes from #CEASAR here: urologytimes.com/view/how-do…
Key takeaways from @ARRO_org graduating resident survey
1️⃣ > 95% got the job type they wanted when they started the process (academic or private)
2️⃣ >90% satisfied with the job they signed
3️⃣ ~15% felt job market was tough this year. DOWN from ~70% in 2019-2020
#astro24
Starting tomorrow, experts from MD Anderson are presenting 48 abstracts at the 2024 American Society For Radiation Oncology (ASTRO) annual meeting.
Learn more about some of the research that will be presented: brnw.ch/21wNfYG@ASTRO_org#ASTRO24#EndCancer